Hematologic, hemostatic, and biochemical effects in cats receiving an oral chondroprotective agent for 30 days.
The objective of this study was to evaluate the effects of a chondroprotective agent on hematologic, hemostatic, and biochemical variables in clinically normal cats when administered at twice the recommended levels for 30 days. Fifteen clinically normal female domestic shorthaired cats were used. Twelve cats were given a chondroprotective agent orally, twice daily for 30 days. Three cats served as environmental controls and did not receive any treatment. The Wilcoxon's rank sum with a Bonferroni correction was used to evaluate the data statistically. Hematologic, hemostatic, and biochemical variables were assessed before treatment and on days 3, 14, and 30 of treatment. All cats remained healthy and showed no adverse reactions to treatment. No clinically and statistically significant shift outside a standard reference range was noted for any parameter. Hematocrit and red blood cell concentrations were decreased from pretreatment concentrations during days 3, 14, and 30 of treatment; however, these values were within a standard reference range at all time points. No significant changes were noted in platelet count, prothrombin time, or activated partial thromboplastin time. There were significant decreases in platelet aggregation response to high and low concentrations of collagen on day 3 and to the high concentration of collagen on days 14 and 30 compared with pretreatment values, but these values were not different from those of untreated cats. There was an increased time to response with the high concentration but not the low concentration of collagen on days 3, 14, and 30. Some parameters, such as potassium, anion gap, alkaline phosphatase, and bicarbonate, showed changes from pretreatment values at some but not all days of treatment. However, median concentrations remained within normal reference ranges, suggesting that these minor shifts were not indicative of clinical significance. Oral chondroprotective agents are widely prescribed in veterinary medicine for the treatment of degenerative joint disease. Safety studies have been performed in dogs; however, to date little is known about the safety of their use in cats. In this study, administration of this chondroprotective agent did not result in any clinically important change in hematologic, biochemical, and hemostatic variables when administered to healthy adult cats for 30 days at twice the recommended dosage.
McNamara
P S
PS
Capital District Veterinary Surgical Associates, 1641 Main Street, Route 5S, Pattersonville, NY 12137, USA.
Barr
S C
SC
Erb
H N
HN
Barlow
L L
LL
D000284:Administration, Oral; D000818:Animals; D001772:Blood Cell Count / Q000662:veterinary*; D002415:Cats / Q000097:blood*; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000009:adverse effects*; D004573:Electrolytes / Q000097:blood; D004798:Enzymes / Q000097:blood; D005260:Female; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000009:adverse effects*; D010974:Platelet Aggregation / Q000187:drug effects; D011517:Prothrombin Time / Q000662:veterinary
D004573:Electrolytes; D004798:Enzymes; D006025:Glycosaminoglycans; C013786:A73025; D002809:Chondroitin Sulfates